Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06393387 · ClinicalTrials.gov registry record
Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States
A clinical trial, sponsored by Midway Specialty Care Center.
- Completed
- Registry status
- 800
- Enrollment target
NCT06393387: Completed study, sponsored by Midway Specialty Care Center.
NCT06393387 is a clinical trial that has completed, run by Midway Specialty Care Center. The registered enrollment target is 800 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06393387 has completed, sponsored by Midway Specialty Care Center.
- COMPLETED
- Registry status
- 800 participants
- Enrollment target
Study Summary
This real-world retrospective study describes the clinical efficacy of 2DR (DOVATO® (DTG/3TC)) versus 3DR (BIKTARVY® (BIC/F/TAF)) in PWH, including those with at least 2 social determinants of health indicators, across a multi clinic infectious disease organization in the Southeast United States
Primary Outcome
To evaluate the effectiveness of switching treatment to DTG/3TC vs. BIC/F/TAF through 48 weeks in virally suppressed ART experienced individuals with no interruptions in prior therapy.
Interventions
- DRUG DTG/3TC versus BIC/F/TAF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2024-06-01 |
| Est. Completion | 2025-04-01 |
What the finished NCT06393387 record still lists
NCT06393387 is an observational study that tracks outcomes without assigning an intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which DTG/3TC versus BIC/F/TAF is the first listed.
NCT06393387 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06393387 about?
NCT06393387 is a clinical study titled "Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States". This real-world retrospective study describes the clinical efficacy of 2DR (DOVATO® (DTG/3TC)) versus 3DR (BIKTARVY® (BIC/F/TAF)) in PWH, including those with at least 2 social determinants of health indicators, across a multi clinic infectious disease organization in the Southeast United States
What is the current status of trial NCT06393387?
This trial is currently completed. The enrollment target is 800 participants. The study started on 2024-06-01. Estimated completion is 2025-04-01.
What interventions are being tested in trial NCT06393387?
The interventions under investigation include: DTG/3TC versus BIC/F/TAF (DRUG).
Who is sponsoring clinical trial NCT06393387?
This trial is sponsored by Midway Specialty Care Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI